XTXavier Thirion

Xavier Thirion

*This is an algorithmically generated author record based on publicly available information.

Xavier Thirion has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • French Specific Surveillance System for Drug Abuse

    by Elisabeth Frauger, Christophe Moracchini, Françoise Albertini, Xavier Thirion, Joëlle Micallef

    It is important to assess drug abuse liability in real life by post-marketing surveillance system. In France, to obtain information on drug abuse liability, the Centers for Evaluation and Information on Pharmacodependence (CEIP) network was created in 1990 with the following aims: detection, prevention, evaluation, and information on drug abuse liability. Its specific work is based on a global, scientific assessment involving preclinical data, clinical studies, and post-marketing surveillance. This network has developed several pharmaco-epidemiological approaches to improve knowledge of drug use in real-life. The aim of this article was to describe a French post-marketing surveillance called OPPIDUM (Observation des Produits Psychotropes Illicites ou Détournés de leur Utilisation Médicamenteuse, Observation of Illegal Drugs and Misuse of Psychotropic Medications). OPPIDUM is an annual cross-sectional survey that collects anonymous information on abuse and dependence observed in patients recruited by specialized care centers dedicated to drug dependence. For each patient included sociodemographic data and psychoactive substance consumptions during the previous week were collected. From 1990 to 2010, a total of 50,734 patients were included with descriptions of 102,631 psychoactive substances. This OPPIDUM data has outlined emergent behaviors, such as use of high dosage buprenorphine by intravenous administration. It has contributed to characterize patients under opiate maintenance treatments and to assess abuse liability of emergent drugs as clonazepam. This pharmacoepidemiologic tool has also detected the decrease of flunitrazepam abuse following implementation of regulatory measures. OPPIDUM’s experience clearly demonstrates that collection of valid and useful data on drug abuse is possible. This post-marketing surveillance system offers important and useful information for physicians and health authorities.


    • 1 January 2013
      • Vol. 16  (1) , 89-100

    Doctor shopping reveals geographical variations in opioid abuse.

    by Sandra Nordmann, Vincent Pradel, Maryse Lapeyre-Mestre, Elisabeth Frauger, Vanessa Pauly, Xavier Thirion, Michel Mallaret, Emilie Jouanjus, Joëlle Micallef

    Prescription opioid abuse is not homogeneous due to varying patterns of use and different geographic preferences. Because doctor shopping is one of the main sources of diversion, it has previously been used to estimate drug abuse. The aim of this study was to describe and compare opioid abuse in 2008 using doctor shopping to estimate abuse in 3 French regions. Data for this study came from the General Health Insurance (GHI) reimbursement database, which covers 77% of the French population. All individuals living in Provence-Alpes-Cote d'Azur-Corse (PACA), Rhone-Alpes (RA), or Midi-Pyrenees (MP) that received at least one reimbursement for oral opioids from the GHI in 2008 were included. Oral opioids under study were opioids for mild to moderate pain (dextropropoxyphene, codeine, tramadol, dihydrocodeine), opoids for moderately severe to severe pain (oral morphine, oxycodone, buprenorphine painkiller, hydromorphone), and opioid maintenance treatments (buprenorphine maintenance, methadone). For a given opioid, the Doctor Shopping Quantity (DSQ) is the quantity obtained by overlapping prescriptions from several prescribers. It is used to estimate the magnitude of abuse. The Doctor Shopping Indicator (DSI) is the DSQ divided by the total dispensed quantity. It is used to estimate the abuse corrected for use. The total DSQ for opioids in PACA (213.3 DDD/1,000 inhabitants) was twofold superior to that in RA (115.1 DDD/1,000) and in MP (106.2 DDD/1,000). The DSQ of opioids for mild to moderate pain was 75.5DDD/1000 (DSI=1.1%), 19.7DDD/1,000 (DSI=5.0%) for opioids for moderately severe to severe pain, and 55.3DDD/1,000 (DSI=6.2%) for opioid maintenance treatments. Emergent signals of abuse have been observed at a regional level for oxycodone in MP and dihydrocodeine in RA and MP. The main limitation of this study is that the GHI reimbursement database provides information about dispensed and reimbursed prescription drugs, and not necessarily the actual quantity used. These results confirm important variations in the 3 French regions despite them being geographically close. Besides, they highlight different rates of opioid abuse between opioids for mild to moderate pain, opioids for moderately severe to severe pain, and opioid maintenance treatments, as well as differences within these groups.


  • Which indicators can public health authorities use to monitor prescription drug abuse and evaluate the impact of regulatory measures? Controlling High Dosage Buprenorphine abuse

    by Vanessa Pauly, Elisabeth Frauger, Vincent Pradel, Franck Rouby, Julie Berbis, François Natali, Patrick Reggio, Hervé Coudert, Joelle Micallef, Xavier Thirion


    • 1 June 2003
      • p. S7-14

    [High-dose buprenorphine prescription in southern France from 1999 to 2001].

    by Julien Mancini, Xavier Thirion, Alain Masut, Eléonore Ronflé, Christine Coudert, Vincent Pradel, Elisabeth Frauger, Joëlle Micallef

    Several reports have focused on prescription of high-dose buprenorphine using data electronically transmitted to the French health reimbursement system. This study deals with high-dose buprenorphine prescriptions in the Bouches-du-Rhone region between 1999 and 2001. We determined the number of maintained patients followed by practitioners (either short- or long-term care), the doses administered, and the associated prescription of psychotropic treatments. The number of general practitioners involved in 84% of the prescriptions of high-dose buprenorphine grew with a high turnover (20%). More than 25% of the general practitioners in the region prescribed this drug, but only 38% of them were involved in long-term follow-up of more than one maintained patient. The number of maintained patients and the mean daily treatment dose delivered (13.4 mg/d during 2001) increased. The associated prescriptions of benzodiazepines concerned 47% of the patients during 2001 (on the rise), but the associated prescription of flunitrazepam tended to decrease (29% of the subjects during 2001 versus 32% during 2000). This study shows a tendency for deviant behaviors to increase, constituting a public health concern.